ALA's platform is based on a technology that - if their clinical data can deliver what their pre-clinical data appears to be suggesting - the one thing these kind of cancer patients don't have, which is a chance to get access to a treatment that does not require to be individually (and time consuming - see the timeline from recruitment to first patient dosed in our CDH17 trial) manufactured using their own cells (autologous), but instead could be readily available in a nearly limitless quantity off-the-shelf. Essentially no waiting time vs 4 weeks (currently). When the patient's life expectancy is measured in months not years, 4 weeks can make a huge difference. The IND process should be fairly streamlined not just for the one product, but the pipeline once they get the nod on the iPSC process since the platform will utilise the same starting material, essentially eliminating or at least reducing the heterogenity that these types of (living) cell therapies bring with them. That in return should hopefully make the therapy more consistent and the effect on patients more predictable. Once granted, they can easily apply for IND's in other areas as well based on promising pre-clinical data.
I can see the value, but as you said, they are still behind in terms of development, which also has something to do with the induced Pluripotent Stem Cell industry in general being fairly new. But it is VERY promising. And that's what ALA investor (not traders) are hoping for.
CHM Price at posting:
1.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)